Bristol-Myers Squibb (NYSE:BMY) was upgraded by equities research analysts at Argus from a “hold” rating to a “buy” rating in a research report issued on Friday, The Fly reports.
A number of other brokerages have also recently commented on BMY. Wolfe Research set a $66.00 price target on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 19th. Morgan Stanley began coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 target price on the stock. Finally, UBS Group increased their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and a consensus target price of $57.95.
BMY opened at $63.94 on Friday. The stock has a market cap of $101.68 billion, a price-to-earnings ratio of 16.07, a PEG ratio of 1.45 and a beta of 0.70. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37. The company’s 50-day moving average price is $57.66 and its two-hundred day moving average price is $50.12. Bristol-Myers Squibb has a twelve month low of $42.48 and a twelve month high of $64.21.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion for the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.09 EPS. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 4.38 earnings per share for the current year.
In other news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.
Several large investors have recently modified their holdings of BMY. Garrett Wealth Advisory Group LLC bought a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth $26,000. Lenox Wealth Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 555.7% during the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. grew its holdings in shares of Bristol-Myers Squibb by 101.2% during the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 327 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Bristol-Myers Squibb by 52.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 230 shares during the last quarter. Finally, 1 North Wealth Services LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $41,000. 83.13% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Can systematic risk be avoided?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.